EUVIMEDEUVIMED entdecken
Multizentrische Studie

Outcome of first-line chemotherapy for anaplastic thyroid cancer—a multicenter registry analysis

Katharina Elisabeth Graf iD, Pia Adam iD, Felix Megerle iD, Yara Maria Machlah iD, Dominik Soll iD, Christina M Berr iD, Ilka Budde, Christian H Pfob iD, Lukas Käsmann, Carmina Teresa Fuß iD, Sarah Küppers, Stefanie Corradini iD und 10 weitere

The Journal of Clinical Endocrinology & Metabolism · 16.09.2026 · 111 (10) · 2861-2870

DOI: 10.1210/clinem/dgag177 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 21.04.2026. Verfasst von Katharina Elisabeth Graf und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine IV, University Hospital Munich, LMU Munich, 80336 Munich, Germany. Hauptthemen laut MEDLINE: Thyroid Carcinoma, Anaplastic, Antineoplastic Combined Chemotherapy Protocols, Thyroid Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: IPSEN.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Prognosis of anaplastic thyroid cancer (ATC) remains poor. In the absence of immediately actionable molecular alterations, guidelines recommend multimodal therapy including radiotherapy and cytotoxic chemotherapy, but optimal regimens are not established. Many centers in Germany have adopted carboplatin/paclitaxel (CP), with or without radiotherapy, as a preferred first-line approach.

Objective

This study aims to compare the outcome of patients treated first-line with CP ± radiotherapy vs other cytotoxic chemotherapy regimens in ATC.

Design

Retrospective multicenter registry study in Germany. Setting and patients 158 adults with histologically confirmed ATC treated with first-line cytotoxic chemotherapy at 7 German tertiary centers (2000-2024). Main Outcome Measures Progression-free survival (PFS) and overall survival (OS) were compared with Kaplan–Meier and log-rank tests; a Cox proportional hazard model was used to identify risk factors.

Results

97 patients received first-line CP, and 61 received other chemotherapy. PFS (102 vs 89 days; log-rank P = .23) and OS (278 vs 295 days; P = .50) did not differ between CP and other regimens. Complete response occurred in 13% with CP and 8% with other chemotherapy (P = .46). In multivariable analyses, age ≥65 years, lymph node metastasis, and distant metastasis were associated with higher mortality risk. Surgery was associated with a lower mortality risk. CP was not associated with improved OS. The outcome of second-line treatment was not different for chemotherapy vs kinase inhibition ± immunotherapy.

Conclusion

In this registry study, CP showed no survival benefit in ATC; outcomes depended on disease burden and resectability, underscoring the need for rapid molecular diagnostics. Chemotherapy may serve as a bridging strategy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid Carcinoma, AnaplasticAntineoplastic Combined Chemotherapy ProtocolsThyroid NeoplasmsHumansFemaleRegistriesMaleAgedRetrospective StudiesMiddle AgedPaclitaxelCarboplatinTreatment OutcomeGermanyPrognosisAdultAged, 80 and over

Stichwörter der Autor:innen

carboplatincytotoxic chemotherapydoxorubicinoverall survivalpaclitaxelprogression-free survival

Substanzen

PaclitaxelCarboplatin

Autor:innen und Institutionen

  • Department of Internal Medicine IV, University Hospital Munich, LMU Munich, 80336 Munich, Germany.
  • Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital Würzburg, University of Würzburg, 97080 Würzburg, Germany.
  • Department of Endocrinology, Diabetology and Metabolism, Endocrine Tumor Center at the West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany.
  • Department of Endocrinology and Metabolism, Charité, Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, European Reference Network on Rare Endocrine Diseases (ENDO-ERN), 10117 Be…
  • Department of Endocrinology, 1st Medical Clinic, University Hospital Augsburg, 86156 Augsburg, Germany.
  • Augsburg Site, Bavarian Cancer Research Center, 86156 Augsburg, Germany.

ORCID-Profile: Katharina Elisabeth Graf, Pia Adam, Felix Megerle, Yara Maria Machlah, Dominik Soll, Christina M Berr, Christian H Pfob, Carmina Teresa Fuß, Stefanie Corradini, Knut Mai, Martin Fassnacht, Tim Brandenburg, Matthias Kroiss

Förderung

  • IPSEN

Zitieren

APA

Graf, K. E., Adam, P., Megerle, F., Machlah, Y. M., Soll, D., Berr, C. M., Budde, I., Pfob, C. H., Käsmann, L., Fuß, C. T., Küppers, S., Corradini, S., Mai, K., Schott, M., Sandner, B., Führer, D., Spitzweg, C., Fassnacht, M., Brandenburg, T., …, & German Study Group for Rare Malignant Tumors of the Thyroid and Parathyroid glands (2026). Outcome of first-line chemotherapy for anaplastic thyroid cancer—a multicenter registry analysis. The Journal of Clinical Endocrinology & Metabolism, 111(10), 2861-2870. https://doi.org/10.1210/clinem/dgag177

Vancouver

Graf KE, Adam P, Megerle F, Machlah YM, Soll D, Berr CM, et al. Outcome of first-line chemotherapy for anaplastic thyroid cancer—a multicenter registry analysis. The Journal of Clinical Endocrinology & Metabolism. 2026;111(10):2861-2870. doi:10.1210/clinem/dgag177

BibTeX
@article{Graf2026,
  author = {Graf, Katharina Elisabeth and Adam, Pia and Megerle, Felix and Machlah, Yara Maria and Soll, Dominik and Berr, Christina M and Budde, Ilka and Pfob, Christian H and Käsmann, Lukas and Fuß, Carmina Teresa and Küppers, Sarah and Corradini, Stefanie and Mai, Knut and Schott, Matthias and Sandner, Benjamin and Führer, Dagmar and Spitzweg, Christine and Fassnacht, Martin and Brandenburg, Tim and Koehler, Viktoria Florentine and Kroiss, Matthias and German Study Group for Rare Malignant Tumors of the Thyroid and Parathyroid glands, German Study Group for Rare Malignant Tumors of the Thyroid and Parathyroid glands},
  title = {Outcome of first-line chemotherapy for anaplastic thyroid cancer—a multicenter registry analysis},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2026},
  volume = {111},
  number = {10},
  pages = {2861--2870},
  doi = {10.1210/clinem/dgag177}
}
Kostenlos starten →